Literature DB >> 11548547

Oxidative damage and metabolic dysfunction in experimental Huntington's disease: selective vulnerability of the striatum and hippocampus.

I D Maksimović1, M D Jovanović, M Colić, R Mihajlović, D Mićić, V Selaković, M Ninković, Z Malicević, M Rusić-Stojiljković, A Jovicić.   

Abstract

The etiology of neuronal death in neurodegenerative diseases, including Huntington's disease (HD), is still unknown. There could be a complex interplay between altered energy metabolism, excitotoxicity and oxidative stress. Unilateral administration of quinilonic acid (QA), NMDA agonist, in rat striatum in a single dose of 150 nM was used as a model of HD. The other two groups of animals were pretreated immediately before QA application with nerve growth factor (NGF) and fibroblast growth factor (FGF), respectively. Control group was treated with 0.9% NaCl in the same manner. Content of total glutathione was not altered in the striatum and hippocampus of QA-treated animals, as well as in the groups pretreated with neurotrophic factors (NF), compared to controls. Content of reduced glutathione, a key antioxidant, was mutually depleted in the striatum and hippocampus of each experimental group. The reduced/total glutathione ratio was decreased in the QA-treated animals, but nearby or over the controls in each structure of the NF-treated groups. These results support the hypothesis that oxygen-free radicals contribute to the excitotoxic neuronal injury, and also that NF could be the potential neuroprotective agents in HD. Moreover, activity of cytochrome c oxidase, the last component in the mitochondrial respiratory chain, was mutually increased in each structure of QA-treated animals. This increase was less pronounced in the NF-treated groups. Striatal lesions led to the loss of tonic inhibitory inputs to the globus pallidus with consequent increase in the activity of GABAergic efferent pallidal neurons, suggesting that NF could functionally repair the altered striopallidal pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11548547

Source DB:  PubMed          Journal:  Vojnosanit Pregl        ISSN: 0042-8450            Impact factor:   0.168


  8 in total

1.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

2.  FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease.

Authors:  Kunlin Jin; Michelle LaFevre-Bernt; Yunjuan Sun; Sylvia Chen; Juliette Gafni; Danielle Crippen; Anna Logvinova; Christopher A Ross; David A Greenberg; Lisa M Ellerby
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-02       Impact factor: 11.205

3.  Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.

Authors:  Trent Nguyen; Aaron Hamby; Stephen M Massa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

4.  Neuroprotective effects of the drug GVT (monosodium luminol) are mediated by the stabilization of Nrf2 in astrocytes.

Authors:  Pichili Vijaya Bhaskar Reddy; Gina Lungu; Xianghong Kuang; George Stoica; Paul K Y Wong
Journal:  Neurochem Int       Date:  2010-03-06       Impact factor: 3.921

5.  Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.

Authors:  Antonio Valencia; Ellen Sapp; Jeffrey S Kimm; Hollis McClory; Patrick B Reeves; Jonathan Alexander; Kwadwo A Ansong; Nicholas Masso; Matthew P Frosch; Kimberly B Kegel; Xueyi Li; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

6.  Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.

Authors:  Xing Guo; Marie-Helene Disatnik; Marie Monbureau; Mehrdad Shamloo; Daria Mochly-Rosen; Xin Qi
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

7.  FGF2 and dual agonist of NCAM and FGF receptor 1, Enreptin, rescue neurite outgrowth loss in hippocampal neurons expressing mutated huntingtin proteins.

Authors:  Mirolyuba Ilieva; Troels T Nielsen; Tanja Michel; Stanislava Pankratova
Journal:  J Neural Transm (Vienna)       Date:  2019-09-09       Impact factor: 3.575

Review 8.  Glucose Metabolic Dysfunction in Neurodegenerative Diseases-New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming.

Authors:  Rongrong Han; Jing Liang; Bing Zhou
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.